These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder. Arlandis S; Castro D; Errando C; Fernández E; Jiménez M; González P; Crespo C; Staeuble F; Rodríguez JM; Brosa M Value Health; 2011; 14(2):219-28. PubMed ID: 21402292 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. Leong RK; de Wachter SG; Joore MA; van Kerrebroeck PE BJU Int; 2011 Aug; 108(4):558-64. PubMed ID: 21166750 [TBL] [Abstract][Full Text] [Related]
4. Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation. Martinson M; MacDiarmid S; Black E J Urol; 2013 Jan; 189(1):210-6. PubMed ID: 23174264 [TBL] [Abstract][Full Text] [Related]
5. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy. Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028 [TBL] [Abstract][Full Text] [Related]
6. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review. Leong RK; De Wachter SG; van Kerrebroeck PE Urol Int; 2010; 84(3):245-53. PubMed ID: 20389150 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. Siddiqui NY; Amundsen CL; Visco AG; Myers ER; Wu JM J Urol; 2009 Dec; 182(6):2799-804. PubMed ID: 19837427 [TBL] [Abstract][Full Text] [Related]
8. To stage or not to stage?-A cost minimization analysis of sacral neuromodulation placement strategies. Sun AJ; Harris CR; Comiter CV; Elliott CS Neurourol Urodyn; 2019 Aug; 38(6):1783-1791. PubMed ID: 31215706 [TBL] [Abstract][Full Text] [Related]
9. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Giannantoni A; Mearini E; Del Zingaro M; Porena M Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955 [TBL] [Abstract][Full Text] [Related]
10. Cost profiles and budget impact of rechargeable versus non-rechargeable sacral neuromodulation devices in the treatment of overactive bladder syndrome. Noblett KL; Dmochowski RR; Vasavada SP; Garner AM; Liu S; Pietzsch JB Neurourol Urodyn; 2017 Mar; 36(3):727-733. PubMed ID: 27062384 [TBL] [Abstract][Full Text] [Related]
11. Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. Padmanabhan P; Scarpero HM; Milam DF; Dmochowski RR; Penson DF World J Urol; 2011 Feb; 29(1):51-7. PubMed ID: 21110030 [TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. Cardozo L; Thorpe A; Warner J; Sidhu M BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203 [TBL] [Abstract][Full Text] [Related]
13. Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System. Bertapelle MP; Vottero M; Popolo GD; Mencarini M; Ostardo E; Spinelli M; Giannantoni A; D'Ausilio A World J Urol; 2015 Aug; 33(8):1109-17. PubMed ID: 25218855 [TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Ko Y; Malone DC; Armstrong EP Pharmacotherapy; 2006 Dec; 26(12):1694-702. PubMed ID: 17125433 [TBL] [Abstract][Full Text] [Related]
15. An overview of treatment of overactive bladder syndrome in women. Allahdin S; Oo N J Obstet Gynaecol; 2012 Apr; 32(3):217-21. PubMed ID: 22369391 [TBL] [Abstract][Full Text] [Related]
16. Solifenacin in the treatment of overactive bladder syndrome in Italian patients: pharmacoeconomic evaluation. Pradelli L; Iannazzo S J Med Econ; 2009 Mar; 12(1):25-35. PubMed ID: 19450062 [TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder. Pelletier EM; Vats V; Clemens JQ Am J Manag Care; 2009 Mar; 15(4 Suppl):S108-14. PubMed ID: 19355799 [TBL] [Abstract][Full Text] [Related]
20. Health economics and intradetrusor injections of botulinum for the treatment of detrusor overactivity. Sangster P; Kalsi V BJU Int; 2008 Jul; 102 Suppl 1():17-9. PubMed ID: 18665974 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]